The global Biopharmaceutical Contract Manufacturing Market is poised for significant growth, with its valuation projected at US$ 10.7 billion in 2024 and expected to reach an impressive US$ 25.1 billion by 2034. This represents a strong CAGR of 8.8% over the forecast period, underscoring the increasing reliance on contract manufacturing services in the biopharmaceutical industry.
The market’s rapid growth is driven by the rising demand for biologics and biosimilars, alongside the need for cost-effective and scalable manufacturing solutions. Outsourcing to contract manufacturing organizations (CMOs) allows biopharmaceutical companies to focus on research and development while leveraging the expertise and advanced technologies provided by CMOs.
Advancements in bioprocessing technologies, including single-use systems and automation, are further enhancing the efficiency and productivity of contract manufacturers. Additionally, the growing trend of partnerships and collaborations between biopharma companies and CMOs is expected to propel the market’s expansion, particularly in emerging markets with burgeoning healthcare industries.
Full Report Revealed – https://www.futuremarketinsights.com/reports/biopharmaceutical-contract-manufacturing-market
Key Takeaways:
- Market Size: Valued at US$ 10.7 billion in 2024, projected to reach US$ 25.1 billion by 2034.
- Growth Rate: Expected to grow at a robust CAGR of 8.8% from 2024 to 2034.
- Market Drivers: Rising demand for biologics, cost-efficient manufacturing solutions, and advancements in bioprocessing technologies.
- Emerging Trends: Increased adoption of single-use systems, automation in biomanufacturing, and growth in emerging markets.
Key Opportunities in the Biopharmaceutical Contract Manufacturing Market
- The demand for biopharmaceuticals, which are typically more complex and difficult to manufacture than traditional chemical drugs is increasing. As a result, many pharmaceutical companies are turning to contract manufacturers to help them produce these drugs at scale, which is expected to create lucrative opportunities in the market.
- Pharmaceutical companies are looking to outsource their manufacturing operations to reduce costs, increase efficiency, and focus on their core competencies.
- This trend is particularly strong in the biopharmaceutical sector, where a high degree of specialization and expertise is required to produce these complex drugs.
- The increasing use of biologics in a wide range of therapeutic areas, the growing demand for personalized medicine, and the emergence of new manufacturing technologies that enable more efficient and cost-effective production of biopharmaceuticals are driving market growth.
- Pharmaceutical companies can benefit from cost savings and efficiency gains that come with outsourcing, allowing them to focus on their core competencies and drive innovation in the biopharmaceutical sector.
Competitive Landscape
The biopharmaceutical contract manufacturing market is becoming increasingly competitive due to the growing demand for biologics and biosimilars.
Companies have a strong reputation for providing high-quality contract manufacturing services to the biopharmaceutical industry. However, there are also several smaller players in the market that are gaining traction and competing with these larger companies by offering specialized services and innovative technologies.
Recent Developments
- In 2021, Lonza Group Ag announced its largest sale of Lonza Speciality Ingredients to Bain Capital Private Equity for US$ 4.4 billion.
- In 2021, bzena Limited, a partner research organization for the integrated discovery of cGMP and a manufacturer of biopharmaceuticals solutions, worked with BiVictriX Therapeutics plc, a biotechnology business, to manufacture BiVictriX’s antibody-drug conjugates (ADC).
- In 2021, Novasep Company formed an exclusive cooperation with PharmaZell. The cooperation aims to develop, manufacture, and expand complicated small compounds and ADCs on a worldwide scale.
Key Market Players
- Catalent Inc.
- Lonza Group Ag
- Patheon N.V. (Thermo Fisher Scientific Inc.)
- Abzena Plc.
- Sandoz International GmbH (Novartis AG)
- Fujifilm Diosynth Biotechnologies (FUJIFILM Holdings)
- Baxter Pharmaceutical Solutions LLC (Baxter Inc.)
- AbbVie Contract Manufacturing (AbbVie Inc.)
- Samsung Biologics Co. Ltd.
- ProBioGen AG
- Pfizer Centre Source Ltd (Pfizer Inc.)
- Novasep
- Biomeva GmbH
- Kbi Biopharma Inc
- Rentschler Biotechnologie GmbH
- Ajinomoto Althea Inc. (Ajinomoto Co., Inc.)
Key Market Segments
By Platform Type:
- Mammalian Based
- Microbial Based
By Product Type:
- Monoclonal Antibodies
- Recombinant Protein
- Vaccine
- Insulin
- Growth factor
- Interferons
- Others
By Application Type:
- Clinical
- Commercial
By Therapeutic Area Type:
- Autoimmune Diseases
- Oncology
- Metabolic Diseases
- Ophthalmology
- Cardiovascular Diseases
- Infectious Diseases
- Neurology
- Respiratory Disorders
- Others
By Region:
- North America
- Latin America
- East Asia
- South Asia
- Europe
- Oceania
- MEA
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube